Mack Gene 4

What Happened

• Mack Gene, CEO, President and a director of Gain Therapeutics (GANX), received a grant of 200,000 derivative shares (reported as an award) on March 24, 2026. The Form 4 lists the per-share price as $0.00 and does not report an immediate cash value. This was an equity award (not an open-market buy or sale).

Key Details

• Transaction type: Award/Grant of derivative securities (code A)
• Transaction date: 2026-03-24; Form 4 filed 2026-03-26 (filed within the typical two-business-day window)
• Amount: 200,000 underlying shares reported; price shown as $0.00 (no dollar value reported on the form)
• Vesting (footnote F1): 25% vests on March 24, 2027; remaining 75% vests in 36 equal monthly installments thereafter, subject to continuous service
• Shares owned after transaction: not specified in the filing

Context

• This is a time‑based equity award (derivative) tied to future vesting and continued service — not an immediate purchase or sale. Such grants are common as executive compensation and do not, by themselves, indicate trading intent or near-term buying/selling of stock.